Long-term predictive value of serum PSA values obtained in clinical practice: Results from the Norwegian Prostate Cancer Consortium (NPCC).
Jan Oldenburg(Akershus University Hospital), Sigrid Carlsson(Memorial Sloan Kettering Cancer Center), Jochen Walz(Institut Paoli-Calmettes), Ola Bratt(Sahlgrenska University Hospital), Kirsti Aas(University of Oslo), Hans Lilja(Memorial Sloan Kettering Cancer Center), Stig Mueller(Akershus University Hospital), Andreas Stensvold(Østfold Hospital Trust), Sophie D. Fosså(Oslo University Hospital), Johan Lars Bjerner, Christoph Mueller(University of Bern), Owen Thomas(Akershus University Hospital), Oluf Dimitri Røe(Norwegian University of Science and Technology)
Cited by 2
Related Papers
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
|Clinical Chemistry|2008|1.1k
Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial
|The Lancet|2008|873
Second Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term Survivors
|JNCI Journal of the National Cancer Institute|2005|830
2022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review
|European Urology|2023|758
Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924
|Journal of Clinical Oncology|2001|628